Cargando…

An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies

PURPOSE: The introduction of magnetic resonance imaging (MRI)-targeted biopsy (TBx) besides systematic prostate biopsies has resulted in a discussion on what the optimal prostate biopsy strategy is. The ideal template has high sensitivity for clinically significant prostate cancer (csPCa), while red...

Descripción completa

Detalles Bibliográficos
Autores principales: Jager, Auke, van Riel, Luigi A.M.J.G., Postema, Arnoud. W., de Reijke, Theo M., van der Sluis, Tim M., Oddens, Jorg R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340407/
https://www.ncbi.nlm.nih.gov/pubmed/35924207
http://dx.doi.org/10.1177/17562872221111410
_version_ 1784760397051461632
author Jager, Auke
van Riel, Luigi A.M.J.G.
Postema, Arnoud. W.
de Reijke, Theo M.
van der Sluis, Tim M.
Oddens, Jorg R.
author_facet Jager, Auke
van Riel, Luigi A.M.J.G.
Postema, Arnoud. W.
de Reijke, Theo M.
van der Sluis, Tim M.
Oddens, Jorg R.
author_sort Jager, Auke
collection PubMed
description PURPOSE: The introduction of magnetic resonance imaging (MRI)-targeted biopsy (TBx) besides systematic prostate biopsies has resulted in a discussion on what the optimal prostate biopsy strategy is. The ideal template has high sensitivity for clinically significant prostate cancer (csPCa), while reducing the detection rate of clinically insignificant prostate cancer (iPCa). This study evaluates different biopsy strategies in patients with a unilateral prostate MRI lesion. METHODS: Retrospective subgroup analysis of a prospectively managed database consisting of patients undergoing prostate biopsy in two academic centres. Patients with a unilateral lesion (PI-RADS ⩾ 3) on MRI were included for analysis. The primary objective was to evaluate the diagnostic performance for different biopsy approaches compared with bilateral systematic prostate biopsy (SBx) and TBx. Detection rates for csPCa (ISUP ⩾ 2), adjusted csPCa (ISUP ⩾ 3) and iPCa (ISUP = 1) were determined for SBx alone, TBx alone, contralateral SBx combined with TBx and ipsilateral SBx combined with TBx. A subgroup analysis was performed for biopsy-naive patients. RESULTS: A total of 228 patients were included from October 2015 to September 2021. Prostate cancer (PCa) detection rate of combined SBx and TBx was 63.5% for csPCa, 35.5% for adjusted csPCa, and 14% for iPCa. The best performing alternative biopsy strategy was TBx and ipsilateral SBx, which reached a sensitivity of 98.6% (95% CI: 95.1–99.6) for csPCa and 98.8% (95% CI: 96.3–99.9) for adjusted csPCa, missing only 1.4% of csPCa, while reducing iPCa detection by 15.6% compared with SBx and TBx. TBx or SBx alone missed a significant amount of csPCa, with sensitivities of 90.3% (95% CI: 84.4–94.2) and 86.8% (95% CI: 80.4–91.4) for csPCa. Subgroup analysis on biopsy-naive patients showed similar results as the overall group. CONCLUSION: This study shows that performing TBx with ipsilateral SBx and omitting contralateral SBx is the optimal biopsy strategy in patients with a unilateral MRI lesion. With this strategy, a very limited amount of csPCa is missed and iPCa detection is reduced.
format Online
Article
Text
id pubmed-9340407
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-93404072022-08-02 An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies Jager, Auke van Riel, Luigi A.M.J.G. Postema, Arnoud. W. de Reijke, Theo M. van der Sluis, Tim M. Oddens, Jorg R. Ther Adv Urol Current Best Practice for Prostate Biopsy: What is the evidence? PURPOSE: The introduction of magnetic resonance imaging (MRI)-targeted biopsy (TBx) besides systematic prostate biopsies has resulted in a discussion on what the optimal prostate biopsy strategy is. The ideal template has high sensitivity for clinically significant prostate cancer (csPCa), while reducing the detection rate of clinically insignificant prostate cancer (iPCa). This study evaluates different biopsy strategies in patients with a unilateral prostate MRI lesion. METHODS: Retrospective subgroup analysis of a prospectively managed database consisting of patients undergoing prostate biopsy in two academic centres. Patients with a unilateral lesion (PI-RADS ⩾ 3) on MRI were included for analysis. The primary objective was to evaluate the diagnostic performance for different biopsy approaches compared with bilateral systematic prostate biopsy (SBx) and TBx. Detection rates for csPCa (ISUP ⩾ 2), adjusted csPCa (ISUP ⩾ 3) and iPCa (ISUP = 1) were determined for SBx alone, TBx alone, contralateral SBx combined with TBx and ipsilateral SBx combined with TBx. A subgroup analysis was performed for biopsy-naive patients. RESULTS: A total of 228 patients were included from October 2015 to September 2021. Prostate cancer (PCa) detection rate of combined SBx and TBx was 63.5% for csPCa, 35.5% for adjusted csPCa, and 14% for iPCa. The best performing alternative biopsy strategy was TBx and ipsilateral SBx, which reached a sensitivity of 98.6% (95% CI: 95.1–99.6) for csPCa and 98.8% (95% CI: 96.3–99.9) for adjusted csPCa, missing only 1.4% of csPCa, while reducing iPCa detection by 15.6% compared with SBx and TBx. TBx or SBx alone missed a significant amount of csPCa, with sensitivities of 90.3% (95% CI: 84.4–94.2) and 86.8% (95% CI: 80.4–91.4) for csPCa. Subgroup analysis on biopsy-naive patients showed similar results as the overall group. CONCLUSION: This study shows that performing TBx with ipsilateral SBx and omitting contralateral SBx is the optimal biopsy strategy in patients with a unilateral MRI lesion. With this strategy, a very limited amount of csPCa is missed and iPCa detection is reduced. SAGE Publications 2022-07-26 /pmc/articles/PMC9340407/ /pubmed/35924207 http://dx.doi.org/10.1177/17562872221111410 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Current Best Practice for Prostate Biopsy: What is the evidence?
Jager, Auke
van Riel, Luigi A.M.J.G.
Postema, Arnoud. W.
de Reijke, Theo M.
van der Sluis, Tim M.
Oddens, Jorg R.
An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies
title An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies
title_full An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies
title_fullStr An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies
title_full_unstemmed An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies
title_short An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies
title_sort optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies
topic Current Best Practice for Prostate Biopsy: What is the evidence?
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340407/
https://www.ncbi.nlm.nih.gov/pubmed/35924207
http://dx.doi.org/10.1177/17562872221111410
work_keys_str_mv AT jagerauke anoptimizedprostatebiopsystrategyinpatientswithaunilaterallesiononprostatemagneticresonanceimagingavoidsunnecessarybiopsies
AT vanrielluigiamjg anoptimizedprostatebiopsystrategyinpatientswithaunilaterallesiononprostatemagneticresonanceimagingavoidsunnecessarybiopsies
AT postemaarnoudw anoptimizedprostatebiopsystrategyinpatientswithaunilaterallesiononprostatemagneticresonanceimagingavoidsunnecessarybiopsies
AT dereijketheom anoptimizedprostatebiopsystrategyinpatientswithaunilaterallesiononprostatemagneticresonanceimagingavoidsunnecessarybiopsies
AT vandersluistimm anoptimizedprostatebiopsystrategyinpatientswithaunilaterallesiononprostatemagneticresonanceimagingavoidsunnecessarybiopsies
AT oddensjorgr anoptimizedprostatebiopsystrategyinpatientswithaunilaterallesiononprostatemagneticresonanceimagingavoidsunnecessarybiopsies
AT jagerauke optimizedprostatebiopsystrategyinpatientswithaunilaterallesiononprostatemagneticresonanceimagingavoidsunnecessarybiopsies
AT vanrielluigiamjg optimizedprostatebiopsystrategyinpatientswithaunilaterallesiononprostatemagneticresonanceimagingavoidsunnecessarybiopsies
AT postemaarnoudw optimizedprostatebiopsystrategyinpatientswithaunilaterallesiononprostatemagneticresonanceimagingavoidsunnecessarybiopsies
AT dereijketheom optimizedprostatebiopsystrategyinpatientswithaunilaterallesiononprostatemagneticresonanceimagingavoidsunnecessarybiopsies
AT vandersluistimm optimizedprostatebiopsystrategyinpatientswithaunilaterallesiononprostatemagneticresonanceimagingavoidsunnecessarybiopsies
AT oddensjorgr optimizedprostatebiopsystrategyinpatientswithaunilaterallesiononprostatemagneticresonanceimagingavoidsunnecessarybiopsies